Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DX002
- Development stage
- Unknown
- Lead developer
- Singlomics (Beijing DanXu) Biopharmaceuticals
- Modality
- Antibody-Based Therapeutics
01
Overview
DX002: sourced facts only. name: "We developed DX002, a fully human agonistic anti-TREM1 monoclonal antibody." [DOI:10.1158/1538-7445.am2025-6083]; target: "We developed DX002, a fully human agonistic anti-TREM1 monoclonal antibody." [DOI:10.1158/1538-7445.am2025-6083]; developer: "Singlomics (Beijing DanXu) Biopharmaceuticals Co., Ltd., Beijing, China." [DOI:10.1158/1538-7445.am2025-6083]; modality: "We developed DX002, a fully human agonistic anti-TREM1 monoclonal antibody." [DOI:10.1158/1538-7445.am2025-6083]; stage: "In vivo, DX002 exhibits significant tumor growth inhibition activity in MC38 syngeneic model in human TREM1 transgenic mice." [DOI:10.1158/1538-7445.am2025-6083]
02
Targets
TREM1 (Triggering receptor expressed on myeloid cells 1)
Beyond the preview
Go deeper on DX002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DX002.